Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

High-dose HspE7 effective and well tolerated in high-grade anal dysplasia

Jan. 14, 2002

Interim analysis of first phase III Provenge trial inconclusive

Jan. 14, 2002

Ceplene plus IL-2 prolongs survival in subset of metastatic melanoma patients

Jan. 14, 2002

Medarex's tumor vaccine program to evaluate melanoma vaccines in conjunction with MDX-010

Jan. 11, 2002

Transgene's Ad-IFNgamma product candidate enters phase I trial for cutaneous lymphoma

Jan. 11, 2002

CD40-targeted MAb moves to clinical development at Genentech

Jan. 10, 2002

HGS and CAT form TRAIL-R1 antibody partnership

Jan. 10, 2002

Abgenix submits IND for ABX-MA1 in metastatic melanoma

Jan. 9, 2002

FDA approves IND for Albuleukin to enter clinical trials in treatment of cancer

Jan. 8, 2002

CancerVax files IND application to conduct pivotal trials of Canvaxin in advanced colon cancer

Jan. 8, 2002

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...